HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vitale, N. Articles by Cotrufo, M. Search for Related Content PubMed PubMed Citation Articles by Vitale, N. Articles by Cotrufo, M.

European Journal of Cardio-Thoracic Surgery, Vol 9, 181-189, Copyright © 1995 by European Association for Cardio-thoracic Surgery

ARTICLES

Long-term follow-up of different models of mechanical and biological mitral prostheses

N Vitale, B Giannolo, GA Nappi, L de Luca, L Piazza, M Scardone and M Cotrufo
Institute of Cardiac Surgery, Medical School, Monaldi Hospital, Naples, Italy.

Three hundred eighty-five valve prostheses were implanted between 1974 and 1981 in patients with isolated mitral disease: 157 caged-ball valves (156 Starr-Edwards; 1 Smeloff-Cutter) (group A), 107 tilting- disc valves (44 Bjork-Shiley, 49 Sorin, 14 Lillehei-Kaster) (group B), 121 porcine bioprostheses (45 Carpentier-Edwards, 66 Liotta, 10 Hancock) (group C). Perioperative mortality was 9.5% in group A, 11.2% in group B and 6.6% in group C. The follow-up was 86% complete. Actuarial freedom from complications was calculated as follows (linearised rates in brackets) in groups A, B and C, respectively: survival: 47.01% +/- 0.11 (3% patient/yr), 53.37% +/- 0.08 (1.8% patient/yr), 61.24% +/- 0.05 (2.2% patient/yr); thromboembolism: 67.94% +/- 0.09 (1.18% patient/yr); 73.07% +/- 0.06 (1% patient/yr); 97.43% +/- 0.02 (0.02% patient/yr); anticoagulation-related hemorrhage: 84.10% +/- 0.13 (0.18% patient/yr), 97.21% +/- 0.01 (0.12% patient/yr), 100%; prosthetic valve endocarditis: 100% in groups A and B, 95.76% +/- 0.02 (0.18% patient/yr) in group C; valve-related mortality: 87.52% +/- 0.03 (0.75% patient/yr), 87.96% +/- 0.03 (0.56% patient/yr), 82.53% +/- 0.04 (0.93% patient/yr); valve failure: 81.22% +/- 0.07 (0.56% patient/yr), 63.36% +/- 0.1 (1.06% patient/yr), 14.31% +/- 0.05 (4% patient/yr); treatment failure: 78.81% +/- 0.05 (1.12% patient/yr), 76.44% +/- 0.09 (0.62% patient/yr), 80.97% +/- 0.04 (1% patient/yr); all valve-related morbidity and mortality: 40.43% +/- 0.13 (1.93% patient/yr), 57.76% +/- 0.08 (1.43% patient/yr), 14.96% +/- 0.05 (4.18% patient/yr); all valve- related morbidity and mortality at 5 years: 91.97% +/- 0.02 (7.8% patient/yr), 87.06% +/- 0.03 (3.6% patient/yr), 90.27% +/- 0.03 (2.6% patient/yr); at 10 years: 80.4% +/- 0.03 (4.6% patient/yr), 75.91% +/- 0.03 (2.6% patient/yr), 37.44% +/- 0.05 (4.18% patient/yr).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				K. Kirali, M. Guler, A. Tuncer, B. Daglar, G. Ipek, O. Isik, and C. Yakut Fifteen-year clinical experience with the Biocor porcine bioprostheses in the mitral position Ann. Thorac. Surg., March 1, 2001; 71(3): 811 - 815. [Abstract] [Full Text] [PDF]

				B. Yamak, B. Mavitas, A. Saritas, S F. Katircioglu, A T. Ulus, L. Birincioglu, Y H. Karagoz, E. Sener, O. Tasdemir, and K. Bayazit Ten-Year Results With Liotta Porcine Bioprostheses in the Mitral Position Asian Cardiovasc Thorac Ann, December 1, 1998; 6(4): 260 - 264. [Abstract] [Full Text] [PDF]